ACADIA Pharmaceuticals Inc.

ACADIA, a San Diego‑based biopharma, develops CNS drugs. Portfolio includes NUPLAZID® for Parkinson’s psychosis, DAYBUE® for Rett, and Phase III candidates for Alzheimer’s and schizophrenia psychosis. Agreements with Neuren and Stoke Therapeutics broaden its RNA‑based platform.

Headquarters: United States (USA)

ACADIA Pharmaceuticals Inc. Logo
Company Profile
  • Employees: 653
  • HQ: San Diego
Traded Instruments
+ Add Instrument 1
Symbol Name Type Exchange Currency ISIN Status Actions
ACAD ACADIA Pharmaceuticals Inc.
Cap: 4.5B | P/E: 17.3
EQUITY NMS USD US0042251084 Active
📈
Home Login